Biometals and Their Therapeutic Implications in Alzheimer’s Disease

Neurotherapeutics

Volumn 12, Issue 1, 2015, Pages 109-120

  Ayton, Scott ^a   Lei, Peng ^a   Bush, Ashley I ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer s disease; Chelation therapy; Copper; Iron; Zinc

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; COPPER; IRON; TRANSITION ELEMENT; ZINC; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; BRAIN REGION; BRAIN SIZE; CLINICAL TRIAL (TOPIC); COGNITION; EXECUTIVE FUNCTION; FENTON REACTION; HUMAN; MOTOR DYSFUNCTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; BRAIN CHEMISTRY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BRAIN CHEMISTRY; COPPER; HUMANS; IRON; NEUROPROTECTIVE AGENTS; ZINC;

EID: 84926617255     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0312-z     Document Type: Review

References (222)

1. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
2. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-4249.
3. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 1986;83:4044-4048.
4. Tanzi RE, Gusella JF, Watkins PC, et al. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235:880-884.
5. Yan R, Bienkowski MJ, Shuck ME, et al. Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. Nature 1999;402:533-537.
6. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999;398:513-517.
7. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-2264.
8. Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369:341-350.
9. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:311-321.
10. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322-333.
11. Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer’s disease. Free Radic Biol Med 2013;62:76-89.
12. Karran E, Hardy J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014;76:185-205.
13. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
14. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 2003;38:547-554.
15. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-223.
16. Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6:144-151.
17. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-2070.
18. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
19. Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 2012;28:49-69.
20. Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 2012;8:261-271.
21. Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-1038.
22. Zhang Y-W, Wang R, Liu Q, Zhang H, Liao F-F, Xu H. Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007;104:10613-10618.
23. Wilcock GK, Black SE, Hendrix SB, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase II trial. Lancet Neurol 2008;7:483-493.
24. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991;349:704-706.
25. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-1013.
26. Jan A, Gokce O, Luthi-Carter R, Lashuel HA. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J Biol Chem 2008;283:28176-28189.
27. Kuperstein I, Broersen K, Benilova I, et al. Neurotoxicity of Alzheimer’s disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio. EMBO J 2010;29:3408-3420.
28. Schilling S, Zeitschel U, Hoffmann T, et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer’s disease-like pathology. Nat Med 2008;14:1106-1111.
29. Schlenzig D, Ronicke R, Cynis H, et al. N-Terminal pyroglutamate formation of Abeta38 and Abeta40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J Neurochem 2012;121:774-784.
30. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA. Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener Dis 2012;10:265-270.
31. Alexandru A, Jagla W, Graubner S, et al. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. J Neurosci 2011;31:12790-12801.
32. Saito T, Suemoto T, Brouwers N, et al. Potent amyloidogenicity and pathogenicity of Aβ43. Nat Neurosci 2011;14:1023-1032.
33. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10:698-712.
34. Lesné S, Koh MT, Kotilinek LA, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006;440:352-357.
35. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-539.
36. Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84.
37. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008;14:837-842.
38. Welzel AT, Maggio JE, Shankar GM, et al. Secreted amyloid beta-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Biochemistry 2014;53:3908-3921.
39. Watt AD, Crespi GA, Down RA, et al. Anti-Abeta antibody target engagement: a response to Siemers et al. Acta Neuropathol 2014;128:611-614.
40. Thornton C, Bright NJ, Sastre M, Muckett PJ, Carling D. AMP-activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J 2011;434:503-512.
41. Zempel H, Thies E, Mandelkow E, Mandelkow E-M. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010;30:11938-11950.
42. Busciglio J, Lorenzo A, Yeh J, Yankner BA. beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 1995;14:879-888.
43. King ME, Kan H-M, Baas PW, Erisir A, Glabe CG, Bloom GS. Tau-dependent microtubule disassembly initiated by prefibrillar beta-amyloid. J Cell Biol 2006;175:541-546.
44. Reifert J, Hartung-Cranston D, Feinstein SC. Amyloid {beta}-mediated cell death of cultured hippocampal neurons reveals extensive tau fragmentation without increased full-length tau phosphorylation. J Biol Chem 2011;286:20797-20811.
45. Ayton S, Lei P. The Aβ-induced NFAT apoptotic pathway is also activated by GSK-3 inhibition: Implications for Alzheimer therapeutics. J Neurosci 2012;32:9454-9456.
46. Hudry E, Wu HY, Arbel-Ornath M, et al. Inhibition of the NFAT pathway alleviates amyloid Beta neurotoxicity in a mouse model of Alzheimer’s disease. J Neurosci 2012;32:3176-3192.
47. Hurtado DE, Molina-Porcel L, Iba M, et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 2010;177:1977-1988.
48. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001;293:1487-1491.
49. Terwel D, Muyllaert D, Dewachter I, et al. Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. Am J Pathol 2008;172:786-798.
50. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging 2008;29:1607-1618.
51. Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem 2007;102:1053-1063.
52. Götz J, Chen F, van Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 2001;293:1491-1495.
53. Ma QL, Lim GP, Harris-White ME, et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 2006;83:374-384.
54. Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer’s disease. J Neurosci 2009;29:7957-7965.
55. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.
56. Liu T, Perry G, Chan HW, et al. Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 2004;88:554-563.
57. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 2002;99:6364-6369.
58. Vossel KA, Zhang K, Brodbeck J, et al. Tau reduction prevents A{beta}-induced defects in axonal transport. Science 2010;330:198.
59. Shipton OA, Leitz JR, Dworzak J, et al. Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J Neurosci 2011;31:1688-1692.
60. Roberson ED, Scearce-Levie K, Palop JJ, et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 2007;316:750-754.
61. Ittner LM, Ke YD, Delerue F, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models. Cell 2010;142:387-397.
62. Roberson ED, Halabisky B, Yoo JW, et al. Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci 2011;31:700-711.
63. Dawson HN, Cantillana V, Jansen M, et al. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer’s disease. Neuroscience 2010;169:516-531.
64. Lei P, Ayton S, Finkelstein DI, et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012;18:291-295.
65. Ma QL, Zuo X, Yang F, et al. Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging. J Neurosci 2014;34:7124-7136.
66. Lei P, Ayton S, Moon S, et al. Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener 2014;9:29.
67. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 2013;12:357-367.
68. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-119.
69. Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the beta-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000;275:19439-19442.
70. Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol 1999;155:853-862.
71. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994;265:1464-1467.
72. Atwood CS, Robinson SR, Smith MA. Amyloid-beta: redox-metal chelator and antioxidant. J Alzheimers Dis 2002;4:203-214.
73. Danscher G, Jensen KB, Frederickson CJ, et al. Increased amount of zinc in the hippocampus and amygdala of Alzheimer’s diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 1997;76:53-59.
74. Panayi AE, Spyrou NM, Iversen BS, White MA, Part P. Determination of cadmium and zinc in Alzheimer’s brain tissue using inductively coupled plasma mass spectrometry. J Neurol Sci 2002;195:1-10.
75. Samudralwar DL, Diprete CC, Ni BF, Ehmann WD, Markesbery WR. Elemental imbalances in the olfactory pathway in Alzheimer’s disease. J Neurol Sci 1995;130:139-145.
76. Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J Neurol Sci 1996;143:137-142.
77. Religa D, Strozyk D, Cherny RA, et al. Elevated cortical zinc in Alzheimer disease. Neurology 2006;67:69-75.
78. Schrag M, Crofton A, Zabel M, et al. Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer’s disease. J Alzheimers Dis 2011;24:137-149.
79. Suh SW, Jensen KB, Jensen MS, et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains. Brain Res 2000;852:274-278.
80. Stoltenberg M, Bruhn M, Sondergaard C, et al. Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. Histochem Cell Biol 2005;123:605-611.
81. Miller LM, Wang Q, Telivala TP, Smith RJ, Lanzirotti A, Miklossy J. Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer’s disease. J Struct Biol 2006;155:30-37.
82. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998;158:47-52.
83. Bush AI, Multhaup G, Moir RD, et al. A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer’s disease. J Biol Chem 1993;268:16109-16112.
84. Lee JY, Cole TB, Palmiter RD, Suh SW, Koh JY. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A 2002;99:7705-7710.
85. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI. Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer’s disease? J Neurosci 2010;30:1631-1636.
86. Lammich S, Kojro E, Postina R, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A 1999;96:3922-3927.
87. Hoke DE, Tan JL, Ilaya NT, et al. In vitro gamma-secretase cleavage of the Alzheimer’s amyloid precursor protein correlates to a subset of presenilin complexes and is inhibited by zinc. FEBS J 2005;272:5544-5557.
88. Greenough MA, Volitaskis I, Li Q-X, et al. Presenilins promote the cellular uptake of copper and zinc and maintain copper chaperone of SOD1-dependent copper/zinc superoxide dismutase activity. J Biol Chem 2011;286:9776-9786.
89. Bush AI, Pettingell WH, Paradis MD, Tanzi RE. Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem 1994;269:12152-12158.
90. Crouch PJ, Tew DJ, Du T, et al. Restored degradation of the Alzheimer’s amyloid-beta peptide by targeting amyloid formation. J Neurochem 2009;108:1198-1207.
91. Boom A, Authelet M, Dedecker R, et al. Bimodal modulation of tau protein phosphorylation and conformation by extracellular Zn2+ in human-tau transfected cells. Biochim Biophys Acta 2009;1793:1058-1067.
92. Mo Z-Y, Zhu Y-Z, Zhu H-L, Fan J-B, Chen J, Liang Y. Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322. J Biol Chem 2009;284:34648-34657.
93. Huang Y, Wu Z, Cao Y, Lang M, Lu B, Zhou B. Zinc binding directly regulates tau toxicity independent of tau hyperphosphorylation. Cell Rep 2014;8:831-842.
94. An W-L, Bjorkdahl C, Liu R, Cowburn RF, Winblad B, Pei J-J. Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J Neurochem 2005;92:1104-1115.
95. Pei J-J, An W-L, Zhou X-W, et al. P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett 2006;580:107-114.
96. Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative diseases. Int J Alz Dis 2011;2011:189246.
97. Ayton S, Lei P. Nigral iron elevation is an invariable feature of Parkinson’s disease and is a sufficient cause of neurodegeneration. Biomed Research Int 2014;2014:581256.
98. Ayton S, Lei P, Adlard PA, et al. Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson’s disease. Mol Neurodegener 2014;9:27.
99. Goodman L. Alzheimer’s disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J Nerv Mental Dis 1953;118:97-130.
100. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains. J Neurosci Res 1992;31:75-83.
101. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J Neurosci Res 1992;31:327-335.
102. Collingwood JF, Mikhaylova A, Davidson M, et al. In situ characterization and mapping of iron compounds in Alzheimer’s disease tissue. J Alzheimers Dis 2005;7:267-272.
103. Baltes C, Princz-Kranz F, Rudin M, Mueggler T. Detecting amyloid-beta plaques in Alzheimer’s disease. Methods Mol Biol 2011;711:511-533.
104. Meadowcroft MD, Connor JR, Smith MB, Yang QX. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer’s disease and APP/PS1 transgenic mice. J Magn Reson Imaging 2009;29:997-1007.
105. Collingwood JF, Chong RK, Kasama T, et al. Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer’s plaque core material. J Alzheimers Dis 2008;14:235-245.
106. Duce JA, Tsatsanis A, Cater MA, et al. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 2010;142:857-867.
107. Andrasi E, Farkas E, Scheibler H, Reffy A, Bezur L. Al, Zn, Cu, Mn and Fe levels in brain in Alzheimer’s disease. Arch Gerontol Geriatr 1995;21:89-97.
108. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997;94:9866-9868.
109. Hare D, Ayton S, Bush A, Lei P. A delicate balance: Iron metabolism and diseases of the brain. Front Aging Neurosci 2013;5:34.
110. Salvador GA, Uranga RM, Giusto NM. Iron and mechanisms of neurotoxicity. Int J Alz Dis 2010;2011:720658.
111. Mark RJ, Hensley K, Butterfield DA, Mattson MP. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death. J Neurosci 1995;15:6239-6249.
112. Ahuja RP, Borchman D, Dean WL, et al. Effect of oxidation on Ca2+ -ATPase activity and membrane lipids in lens epithelial microsomes. Free Radic Biol Med 1999;27:177-185.
113. Moreau VH, Castilho RF, Ferreira ST, Carvalho-Alves PC. Oxidative damage to sarcoplasmic reticulum Ca2 + -ATPase AT submicromolar iron concentrations: evidence for metal-catalyzed oxidation. Free Radic Biol Med 1998;25:554-560.
114. Kaplan P, Matejovicova M, Mezesova V. Iron-induced inhibition of Na+, K(+)-ATPase and Na+/Ca2+ exchanger in synaptosomes: protection by the pyridoindole stobadine. Neurochem Res 1997;22:1523-1529.
115. Gnana-Prakasam JP, Thangaraju M, Liu K, et al. Absence of iron-regulatory protein Hfe results in hyperproliferation of retinal pigment epithelium: role of cystine/glutamate exchanger. Biochem J 2009;424:243-252.
116. Yu J, Guo Y, Sun M, Li B, Zhang Y, Li C. Iron is a potential key mediator of glutamate excitotoxicity in spinal cord motor neurons. Brain Res 2009;1257:102-107.
117. Mitchell RM, Lee SY, Simmons Z, Connor JR. HFE polymorphisms affect cellular glutamate regulation. Neurobiol Aging 2011;32:1114-1123.
118. Pedersen WA, Fu W, Keller JN, et al. Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients. Ann Neurol 1998;44:819-824.
119. Pedersen WA, Chan SL, Mattson MP. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem 2000;74:1426-1433.
120. Keller JN, Mark RJ, Bruce AJ, et al. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes. Neuroscience 1997;80:685-696.
121. Strugatsky D, Gottschalk KE, Goldshleger R, Bibi E, Karlish SJ. Expression of Na+, K+-ATPase in Pichia pastoris: analysis of wild type and D369N mutant proteins by Fe2+-catalyzed oxidative cleavage and molecular modeling. J Biol Chem 2003;278:46064–46073.
122. Munoz P, Humeres A, Elgueta C, Kirkwood A, Hidalgo C, Nunez MT. Iron mediates N-methyl-D-aspartate receptor-dependent stimulation of calcium-induced pathways and hippocampal synaptic plasticity. J Biol Chem 2011;286:13382-13392.
123. Jiang X, Mu D, Biran V, et al. Activated Src kinases interact with the N-methyl-D-aspartate receptor after neonatal brain ischemia. Ann Neurol 2008;63:632-641.
124. Nakamichi N, Ohno H, Nakamura Y, Hirai T, Kuramoto N, Yoneda Y. Blockade by ferrous iron of Ca2+ influx through N-methyl-D-aspartate receptor channels in immature cultured rat cortical neurons. J Neurochem 2002;83:1-11.
125. Shinkyo R, Guengerich FP. Cytochrome P450 7A1 cholesterol 7alpha-hydroxylation: individual reaction steps in the catalytic cycle and rate-limiting ferric iron reduction. J Biol Chem 2011;286:4632-4643.
126. Graham RM, Chua AC, Carter KW, et al. Hepatic iron loading in mice increases cholesterol biosynthesis. Hepatology 2010;52:462-471.
127. Kraml PJ, Klein RL, Huang Y, Nareika A, Lopes-Virella MF. Iron loading increases cholesterol accumulation and macrophage scavenger receptor I expression in THP-1 mononuclear phagocytes. Metabolism 2005;54:453-459.
128. Francis N, Wong SH, Hampson P, et al. Lactoferrin inhibits neutrophil apoptosis via blockade of proximal apoptotic signaling events. Biochim Biophys Acta 2011;1813:1822-1826.
129. Yurkova I, Kisel M, Arnhold J, Shadyro O. Iron-mediated free-radical formation of signaling lipids in a model system. Chem Phys Lipids 2005;137:29-37.
130. Yehuda S, Rabinovitz-Shenkar S, Carasso RL. Effects of essential fatty acids in iron deficient and sleep-disturbed attention deficit hyperactivity disorder (ADHD) children. Eur J Clin Nutr 2011;65:1167-1169.
131. LeBlanc CP, Fiset S, Surette ME, Turgeon O’Brien H, Rioux FM. Maternal iron deficiency alters essential fatty acid and eicosanoid metabolism and increases locomotion in adult guinea pig offspring. J Nutr 2009;139:1653-1659.
132. Brown KE, Dennery PA, Ridnour LA, et al. Effect of iron overload and dietary fat on indices of oxidative stress and hepatic fibrogenesis in rats. Liver Int 2003;23:232-242.
133. Dougherty JJ, Croft WA, Hoekstra WG. Effects of ferrous chloride and iron dextran on lipid peroxidation in vivo in vitamin E and selenium adequate and deficient rats. J Nutr 1981;111:1784-1796.
134. Isaac G, Fredriksson A, Danielsson R, Eriksson P, Bergquist J. Brain lipid composition in postnatal iron-induced motor behavior alterations following chronic neuroleptic administration in mice. FEBS J 2006;273:2232-2243.
135. Jenkins KJ, Kramer JK. Effect of excess dietary iron on lipid composition of calf liver, heart, and skeletal muscle. J Dairy Sci 1988;71:435-441.
136. Mattson MP. Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders. Ann N Y Acad Sci 2004;1012:37-50.
137. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060-1072.
138. Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007;447:864-868.
139. Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol 2008;15:234-245.
140. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 2002;277:45518-45528.
141. Li X, Liu Y, Zheng Q, et al. Ferritin light chain interacts with PEN-2 and affects gamma-secretase activity. Neurosci Lett 2013;548:90-94.
142. Becerril-Ortega J, Bordji K, Freret T, Rush T, Buisson A. Iron overload accelerates neuronal amyloid-beta production and cognitive impairment in transgenic mice model of Alzheimer’s disease. Neurobiol Aging 2014;35:2288-2301.
143. Mantyh PW, Ghilardi JR, Rogers S, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993;61:1171-1174.
144. Huang X, Atwood CS, Moir RD, Hartshorn MA, Tanzi RE, Bush AI. Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer’s Abeta peptides. J Biol Inorg Chem 2004;9:954-960.
145. Schubert D, Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 1995;216:702-707.
146. Liu B, Moloney A, Meehan S, et al. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 2011;286:4248-4256.
147. Rottkamp CA, Raina AK, Zhu XW, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 2001;30:447-450.
148. Rival T, Page RM, Chandraratna DS, et al. Fenton chemistry and oxidative stress mediate the toxicity of the beta-amyloid peptide in a Drosophila model of Alzheimer’s disease. Eur J Neurosci 2009;29:1335-1347.
149. Kuperstein F, Yavin E. Pro-apoptotic signaling in neuronal cells following iron and amyloid beta peptide neurotoxicity. J Neurochem 2003;86:114-125.
150. García de Ancos J, Correas I, Avila J. Differences in microtubule binding and self-association abilities of bovine brain tau isoforms. J Biol Chem 1993;268:7976-7982.
151. Ledesma MD, Avila J, Correas I. Isolation of a phosphorylated soluble tau fraction from Alzheimer’s disease brain. Neurobiol Aging 1995;16:515-522.
152. Yamamoto A, Shin R-W, Hasegawa K, et al. Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer’s disease. J Neurochem 2002;82:1137-1147.
153. Lovell MA, Xiong S, Xie C, Davies PL, Markesbery WR. Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis 2004;6:659-671.
154. Chan A, Shea TB. Dietary and genetically-induced oxidative stress alter tau phosphorylation: influence of folate and apolipoprotein E deficiency. J Alzheimers Dis 2006;9:399-405.
155. Huang X, Dai J, Huang C, Zhang Q, Bhanot O, Pelle E. Deferoxamine synergistically enhances iron-mediated AP-1 activation: a showcase of the interplay between extracellular-signal-regulated kinase and tyrosine phosphatase. Free Radic Res 2007;41:1135-1142.
156. Muñoz P, Zavala G, Castillo K, Aguirre P, Hidalgo C, Nuñez MT. Effect of iron on the activation of the MAPK/ERK pathway in PC12 neuroblastoma cells. Biol Res 2006;39:189-190.
157. Ksiezak-Reding H, Binder LI, Yen S-HC. Immunochemical and biochemical characterization of tau proteins in normal and Alzheimer’s disease brains with Alz 50 and Tau-1. J Biol Chem 1988;263:7948-7953.
158. Khatoon S, Grundke-Iqbal I, Iqbal K. Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett 1994;351:80-84.
159. Zhukareva V, Sundarraj S, Mann D, et al. Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementias: an international follow-up study. Acta Neuropathol 2003;105:469-476.
160. van Eersel J, Bi M, Ke YD, et al. Phosphorylation of soluble tau differs in Pick’s disease and Alzheimer’s disease brains. J Neural Transm 2009;116:1243-1251.
161. McCarthy RC, Park YH, Kosman DJ. sAPP modulates iron efflux from brain microvascular endothelial cells by stabilizing the ferrous iron exporter ferroportin. EMBO Rep 2014;15:809-815.
162. Ayton S, Zhang M, Roberts BR, et al. Ceruloplasmin and beta-amyloid precursor protein confer neuroprotection in traumatic brain injury and lower neuronal iron. Free Radic Biol Med 2014;69:331-337.
163. Madsen E, Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 2007;30:317-337.
164. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205-214.
165. Barnham KJ, Ciccotosto GD, Tickler AK, et al. Neurotoxic, redox-competent Alzheimer’s beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 2003;278:42959-42965.
166. Puglielli L, Friedlich AL, Setchell KDR, et al. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest 2005;115:2556-2563.
167. Robinson NJ, Winge DR. Copper metallochaperones. Annu Rev Biochem 2010;79:537-562.
168. Ayton S, Lei P, Duce JA, et al. Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease. Ann Neurol 2013;73:554-559.
169. Wong BX, Ayton S, Lam LQ, et al. A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe under physiologically relevant conditions. Biochim Biophys Acta 2014;1840:3299-3310.
170. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995;92:2539-2543.
171. Talmard C, Guilloreau L, Coppel Y, Mazarguil H, Faller P. Amyloid-beta peptide forms monomeric complexes with Cu(II) and Zn(II) prior to aggregation. Chembiochem 2007;8:163-165.
172. Atwood CS, Moir RD, Huang X, et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 1998;273:12817-12826.
173. Jiao Y, Han DX, Yang P. Molecular modeling of the inhibitory mechanism of copper(II) on aggregation of amyloid beta-peptide. Sci China Ser B 2005;48:580-590.
174. Jiao Y, Yang P. Mechanism of copper(II) inhibiting Alzheimer’s amyloid beta-peptide from aggregation: a molecular dynamics investigation. J Phys Chem B 2007;111:7646-7655.
175. Tõugu V, Karafin A, Zovo K, et al. Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem 2009;110:1784-1795.
176. Wu W-h, Lei P, Liu Q, et al. Sequestration of copper from beta-amyloid promotes selective lysis by cyclen-hybrid cleavage agents. J Biol Chem 2008;283:31657-31664.
177. Perrone L, Mothes E, Vignes M, et al. Copper transfer from Cu-Abeta to human serum albumin inhibits aggregation, radical production and reduces Abeta toxicity. Chembiochem 2010;11:110-118.
178. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999;38:7609-7616.
179. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999;274:37111-37116.
180. Jiang D, Men L, Wang J, et al. Redox reactions of copper complexes formed with different beta-amyloid peptides and their neuropathological relevance. Biochemistry 2007;46:9270-9282.
181. Butterfield DA, Pocernich CB. The glutamatergic system and Alzheimer’s disease: therapeutic implications. CNS Drugs 2003;17:641-652.
182. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease: investigative and therapeutic perspectives. J Neurochem 1993;60:1589-1604.
183. Hopt A, Korte S, Fink H, et al. Methods for studying synaptosomal copper release. J Neurosci Methods 2003;128:159-172.
184. Hartter DE, Barnea A. Evidence for release of copper in the brain: depolarization-induced release of newly taken-up 67copper. Synapse 1988;2:412-415.
185. Schlief ML, Craig AM, Gitlin JD. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci 2005;25:239-246.
186. Schlief ML, West T, Craig AM, Holtzman DM, Gitlin JD. Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A 2006;103:14919-14924.
187. Soragni A, Zambelli B, Mukrasch MD, et al. Structural characterization of binding of Cu(II) to tau protein. Biochemistry 2008;47:10841-10851.
188. Ma QF, Li YM, Du JT, et al. Binding of copper (II) ion to an Alzheimer’s tau peptide as revealed by MALDI-TOF MS, CD, and NMR. Biopolymers 2005;79:74-85.
189. Ma Q, Li Y, Du J, et al. Copper binding properties of a tau peptide associated with Alzheimer’s disease studied by CD, NMR, and MALDI-TOF MS. Peptides 2006;27:841-89.
190. Zhou LX, Du JT, Zeng ZY, et al. Copper (II) modulates in vitro aggregation of a tau peptide. Peptides 2007;28:2229-2234.
191. Su XY, Wu WH, Huang ZP, et al. Hydrogen peroxide can be generated by tau in the presence of Cu(II). Biochem Biophys Res Commun 2007;358:661-665.
192. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals. J Neurochem 2000;74:270-279.
193. Kitazawa M, Cheng D, Laferla FM. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 2009;108:1550-1560.
194. Crouch PJ, Hung LW, Adlard PA, et al. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 2009;106:381-386.
195. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 2000;20(Suppl.):S20–S24.
196. Cherny RA, Atwood CS, Xilinas ME, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001;30:665-676.
197. Di Vaira M, Bazzicalupi C, Orioli P, Messori L, Bruni B, Zatta P. Clioquinol, a drug for Alzheimer’s disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem 2004;43:3795-3797.
198. Treiber C, Simons A, Strauss M, et al. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer’s disease. Biol Chem 2004;279:51958-51964.
199. Raman B, Ban T, Yamaguchi K-i, et al. Metal ion-dependent effects of Clioquinol on the fibril growth of an amyloid {beta} peptide. J Biol Chem 2005;280:16157-16162.
200. Priel T, Aricha-Tamir B, Sekler I. Clioquinol attenuates zinc-dependent beta-cell death and the onset of insulitis and hyperglycemia associated with experimental type I diabetes in mice. Eur J Pharmacol 2007;565:232-239.
201. Barrea RA, Chen D, Irving TC, Dou QP. Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol’s anticancer activity. J Cell Biochem 2009;108:96-105.
202. Nitzan YB, Sekler I, Frederickson CJ, et al. Clioquinol effects on tissue chelatable zinc in mice. J Mol Med (Berl) 2003;81:637-644.
203. Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008;59:43-55.
204. Li C, Wang J, Zhou B. The metal chelating and chaperoning effects of clioquinol: insights from yeast studies. J Alzheimers Dis 2010;21:1249-1262.
205. Park MH, Lee SJ, Byun HR, et al. Clioquinol induces autophagy in cultured astrocytes and neurons by acting as a zinc ionophore. Neurobiol Dis 2011;42:242-251.
206. Crouch PJ, Savva MS, Hung LW, et al. The Alzheimer’s therapeutic PBT2 promotes amyloid-beta degradation and GSK3 phosphorylation via a metal chaperone activity. J Neurochem 2011;119:220-230.
207. Atamna H, Frey WH. A role for heme in Alzheimer’s disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci U S A 2004;101:11153-11158.
208. Choi SM, Choi KO, Park YK, Cho H, Yang EG, Park H. Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells. J Biol Chem 2006;281:34056-34063.
209. Felkai S, Ewbank JJ, Lemieux J, Labbe JC, Brown GG, Hekimi S. CLK-1 controls respiration, behavior and aging in the nematode Caenorhabditis elegans. EMBO J 1999;18:1783-1792.
210. Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 2003;37:899-909.
211. LeVine H, 3rd, Ding Q, Walker JA, Voss RS, Augelli-Szafran CE. Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly. Neurosci Lett 2009;465:99-103.
212. Mancino AM, Hindo SS, Kochi A, Lim MH. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited. Inorg Chem 2009;48:9596-9598.
213. Stoppelkamp S, Bell HS, Palacios-Filardo J, Shewan DA, Riedel G, Platt B. In vitro modelling of Alzheimer’s disease: degeneration and cell death induced by viral delivery of amyloid and tau. Exp Neurol 2011;229:226-237.
214. Grossi C, Francese S, Casini A, et al. Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis 2009;17:423-440.
215. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685-1691.
216. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer’s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008;7:779-786.
217. Faux NG, Ritchie CW, Gunn AP, et al. PBT2 rapidly improves cognition in Alzheimer’s Disease: additional phase II analyses. J Alzheimers Dis 2010;20:509-516.
218. Cherny RA, Ayton S, Finkelstein DI, Bush AI, McColl G, Massa SM. PBT2 reduces toxicity in a C. elegans model of polyQ aggregation and extends lifespan, reduces striatal atrophy and improves motor performance in the R6/2 mouse model of Huntington’s disease. J Huntingtons Dis 2012;1:211-219.
219. Donnelly PS, Caragounis A, Du T, et al. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 2008;283:4568-4577.
220. Hung LW, Villemagne VL, Cheng L, et al. The hypoxia imaging agent CuII(atsm) is neuroprotective and improves motor and cognitive functions in multiple animal models of Parkinson’s disease. J Exp Med 2012;209:837-854.
221. Crapper McLachlan DR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 1991;337:1304-1308.
222. Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal 2014;21:195-210.